Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0085631 (
agitation
)
12,064
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A recombinant yeast, Saccharomyces cerevisiae, expressing Escherichia coli beta-galactosidase gene under the control of
CYC1
constitutive promoter of the yeast, was disrupted in a continuous flow, high speed, bead mill for the release of intracellular beta-galactosidase (EC 3.2.1.23). Release of the beta-galactosidase activity was characterized with respect to glass bead loading in the grinding chamber (70-85% of chamber volume), diameter of the beads (0.25-0.75 mm), number of passes of the cell slurry through the mill (0-6 passes), flow rate of the slurry (25-250 mL.min-1), cell concentration in the slurry (5-20 gDW.L-1), the
agitation
rotor speed (1000-4000 rpm) and the pH of the slurry (pH 5-10). The optimal conditions for the release of the enzyme were pH 6.0-9.0, 85% loading of 0.5 mm diameter beads and an
agitation
speed of 2000 rpm. The enzyme release followed first-order kinetics. For otherwise fixed conditions, the extent of cell disruption increase with increasing bead load, number of passes and
agitation
rotor speed. Cell concentration did not affect disruption. The release of beta-galactosidase activity declined with increasing flow rate of the cell slurry through the mill, but the disruption rate constant increased with flow rate. Under optimal condition, three passes through the grinding chamber were sufficient to release all of the enzyme. In comparison with disruption in the bead mill, chloroform-sodium dodecyl sulfate induced lysis of cells was ineffective in releasing the enzyme quantitatively.
...
PMID:Disruption of a recombinant yeast for the release of beta-galactosidase. 776 95